Literature DB >> 11745831

Postmarketing surveillance for human teratogenicity: a model approach.

C D Chambers1, S R Braddock, G G Briggs, A Einarson, Y R Johnson, R K Miller, J E Polifka, L K Robinson, K Stepanuk, K Lyons Jones.   

Abstract

BACKGROUND: Most congenital defects associated with prenatal exposures are notable for a pattern of major and minor malformations, rather than for a single major malformation. Thus, traditional epidemiological methods are not universally effective in identifying new teratogens. The purpose of this report is to outline a complementary approach that can be used in addition to other more established methods to provide the most comprehensive evaluation of prenatal exposures with respect to teratogenicity.
METHODS: We describe a multicenter prospective cohort study design involving dysmorphological assessment of liveborn infants. This design uses the Organization of Teratology Information Services, a North American network of information providers who also collaborate for research purposes. Procedures for subject selection, methods for data collection, standard criteria for outcome classification, and the approach to analysis are detailed.
RESULTS: The focused cohort study design allows for evaluation of a spectrum of adverse pregnancy outcomes ranging from spontaneous abortion to functional deficit. While sample sizes are typically inadequate to identify increased risks for single major malformations, the use of dysmorphological examinations to classify structural anomalies provides the unique advantage of screening for a pattern of malformation among exposed infants.
CONCLUSIONS: As the known human teratogens are generally associated with patterns of structural defects, it is only when studies of this type are used in combination with more traditional methods that we can achieve an acceptable level of confidence regarding the risk or safety of specific exposures during pregnancy. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745831     DOI: 10.1002/tera.1071

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  13 in total

1.  A nonparametric maximum likelihood approach for survival data with observed cured subjects, left truncation and right-censoring.

Authors:  Jue Hou; Christina D Chambers; Ronghui Xu
Journal:  Lifetime Data Anal       Date:  2017-12-13       Impact factor: 1.588

2.  Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials.

Authors:  Sonja A Rasmussen; Sonia Hernandez-Diaz; Omar A Abdul-Rahman; Leyla Sahin; Carey R Petrie; Kim M Keppler-Noreuil; Sharon E Frey; Robin M Mason; Mirjana Nesin; John C Carey
Journal:  Clin Infect Dis       Date:  2014-12-15       Impact factor: 9.079

3.  Birth outcomes in women who have taken leflunomide during pregnancy.

Authors:  Christina D Chambers; Diana L Johnson; Luther K Robinson; Stephen R Braddock; Ronghui Xu; Janina Lopez-Jimenez; Nicole Mirrasoul; Elizabeth Salas; Yunjun J Luo; Shelia Jin; Kenneth Lyons Jones
Journal:  Arthritis Rheum       Date:  2010-05

Review 4.  Pregnancy exposure registries.

Authors:  Dianne L Kennedy; Kathleen Uhl; Sandra L Kweder
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Challenges in Studying Modifiable Risk Factors for Birth Defects.

Authors:  Sarah C Tinker; Suzanne Gilboa; Jennita Reefhuis; Mary M Jenkins; Marcy Schaeffer; Cynthia A Moore
Journal:  Curr Epidemiol Rep       Date:  2015-03

6.  Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions.

Authors:  Chelsey J F Smith; Kenneth L Jones; Diana L Johnson; Gretchen Bandoli; Loan K Robinson; Arthur Kavanaugh; Christina D Chambers
Journal:  Am J Med Genet A       Date:  2018-01-17       Impact factor: 2.802

7.  Acetaminophen use in pregnancy: Examining prevalence, timing, and indication of use in a prospective birth cohort.

Authors:  Gretchen Bandoli; Kristin Palmsten; Christina Chambers
Journal:  Paediatr Perinat Epidemiol       Date:  2019-11-07       Impact factor: 3.980

Review 8.  COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?

Authors:  Helen Dolk; Christine Damase-Michel; Joan K Morris; Maria Loane
Journal:  Paediatr Perinat Epidemiol       Date:  2022-03-02       Impact factor: 3.103

Review 9.  Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data.

Authors:  Christina D Chambers; Zuhre N Tutuncu; Diana Johnson; Kenneth L Jones
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

10.  How physicians perceive and utilize information from a teratogen information service: the Motherisk Program.

Authors:  Adrienne Einarson; Andrew Park; Gideon Koren
Journal:  BMC Med Educ       Date:  2004-04-05       Impact factor: 2.463

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.